Navigation Links
Large-Scale Meta-Analysis Shows Age Not a Social Barrier to Opioid Use and Misuse
Date:5/17/2012

BALTIMORE, May 17, 2012 /PRNewswire/ -- Ameritox (SM), the nation's leader in pain medication monitoring, announced today the presentation of a peer-reviewed scientific poster titled "Patterns of Drug Use in the Older Chronic Pain Population" at the American Pain Society Annual Meeting.  Ameritox researchers will share analysis from 725,679 urine drug monitoring samples from chronic pain patients aged 50 and older.  Data show almost one-third (31.8 percent) lacked the physician-prescribed pain medication in clinically sampled urine, and more than a quarter (28 percent) of patients' samples contained a prescription drug not prescribed by the doctor ordering the monitoring test.

Although the common perception is that America's prescription drug misuse concerns should focus on the young, data suggest that older pain patients have the same issues with potential non-adherence and medication misuse as the overall chronic-pain population. The Ameritox study suggests health professionals should put aside age as a predictive indicator in evaluating medication adherence. The study concludes that there is a significant potential for non-adherence in the older population.

"This study provides strong evidence that there are two major reasons to monitor medication use, using urine drug testing, in older patients with chronic pain. The first is that this population has a risk of medication misuse and illicit drug use that warrants attention," said Dr. Harry Leider, Chief Medical Officer of Ameritox. "The second is that a powerful medication was found in one in four older patients -- one that the doctor prescribing a pain medication was not aware of. This data provides a compelling rationale for routinely monitoring medication use in older patients on chronic opioids."

An additional factor that drives a portion of medication misuse in older patients is the use of multiple medications, prescribed by different physicians, for multiple chronic conditions.  This places the older population at a higher risk for dangerous drug-drug interactions. In addition, older patients may not remember or keep track of all of their medications prescribed by various physicians. Common side effects and interactions that can occur as a result include: constipation, mental status changes, depression and falls. Drug monitoring can help provide physicians with a more complete picture of a patient's medication use prior to a serious event occurring.

The "Patterns of Drug Use in the Older Chronic Pain Population" poster was co-authored by Lisa Burke, PhD, MBA, RN, and Monica Fay, PharmD, MBA, associate medical directors at Ameritox, who examined extensive data of urine drug monitoring results taken from patient samples of those 50 years and older and submitted for analysis to Ameritox from October 1, 2009 to September 30, 2011; a total of 725,679 samples.  Results of this testing revealed:

  • 7.6% had an illicit drug detected (e.g., marijuana, cocaine metabolite, heroin metabolite or PCP)
  • 28.1% had a non-prescribed drug detected (e.g., opiates, benzodiazepines, barbiturates, etc.)
  • 31.8% did not have a prescribed drug detected (e.g., a prescribed pain medication)
  • 45.9% of samples had no abnormality found.

These data are similar to findings of a 2009 study[i] of more than 900,000 samples taken from individuals across age groups.  Therefore, presenters suggest that "age may not be a predominate factor in the likelihood of misuse or abuse of drugs."   Frequently, older patients are perceived as more adherent to their physicians' prescribed drug regimen.  These large-scale urine drug test studies show that monitoring could aid significantly in helping physicians[ii] identify clinical inconsistencies and should augment patient self-reporting[iii]. 

The American Pain Society and American Academy of Pain Medicine clinical recommendations support pain medication monitoring as a tool to help confirm whether patients adhere to their prescribed drug regimen.

"Older adults are the fastest growing subset of the U.S. population and one of the largest groups of chronic pain patients," said Lisa Burke, PhD, MBA, RN, Ameritox.  "With physicians increasingly on the front lines of patient care and public safety, pain medication monitoring, through urine drug testing, is an important tool to help clinicians ensure their patients – regardless of their age – receive the best possible care and achieve relief from chronic pain."

The U.S. Department of Health and Human Services Administration on Aging reports the older population -- persons 65 years or older -- numbered 39.6 million in 2009 (the latest year for which data are available). This age group then represented only 12.9% of the U.S. population, approximately one in every eight Americans. By 2030, there will be about 72.1 million older persons, more than twice their number in 2000.

About Ameritox
Ameritox is the nation's leader in Pain Medication Monitoring Solutions®, offering specialized laboratory testing and reporting services. Ameritox's expertise and innovative science provide physicians with insights and support to enhance and optimize the care of chronic pain patients. Ameritox offers the most thorough pain medication monitoring lab process – Rx Guardian(SM) – with Rx Guardian CD(SM), the only pain medication monitoring process with a proprietary normalization algorithm and a reference database of pain patients clinically assessed for medication adherence. Patient results are compared against this database, helping physicians assess whether patients are taking their pain medications correctly. Monitoring through prescription drug testing helps physicians make more informed clinical decisions and manage the risks and complexities associated with prescribing pain medications. Ameritox is headquartered in Baltimore, Md. with laboratory facilities in Midland, Texas and Greensboro, N.C. Ameritox can be found online at www.ameritox.com, on Twitter@Ameritox, or on Facebook at facebook.com/ameritox.

© 2011 Ameritox Ltd. All rights reserved. AMERITOX, the AMERITOX logos, AMERITOX AUTOREMINDER, AMERITOX MEDICATION MONITORING SOLUTIONS, AMERITOX UNIVERSITY, PAIN MEDICATION MONITORING SOLUTIONS, POWERED BY YOUR NEED TO KNOW and PROTECT YOUR PATIENTS. PROTECT YOUR PRACTICE. RX GUARDIAN, RX GUARDIAN CD, and RX GUARDIAN AUTOREMINDER are trademarks of Ameritox.

[i] Couto, JE, Romney, MC, Leider, H.L., et al. (2009). High rates of inappropriate drug use in the chronic pain population.  Population Health Management[i]

[ii] Katz NP, et al. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg. 2003;97(4):1097–102.

[iii] Atluri S, Sudarshan G. Evaluation of abnormal urine drug screens among patients with chronic non-malignant pain treated with opioids. Pain Physician. 2003;6:407–9.

For more information, contact: Lon Wagner
Ameritox
336-387-7742
Lon.Wagner@ameritox.com

 


'/>"/>
SOURCE Ameritox
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Medical Systems Announces Large-Scale, Physician-Led Registry of Penile Implants
2. Kaiser Permanente Demonstrates Success of Large-Scale Total Joint Replacement Registry
3. One-Third of Antimalarial Medicines Sampled in Three African Nations Found to Be Substandard in Large-Scale USP-WHO Study
4. New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
5. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
6. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
7. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
8. Signal Genetics Announces Publication of Meta-Analysis of its Colon Cancer Test-Previstage™ GCC Confirming Prognostic Capabilities in Patients with Colon Cancer
9. Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment
10. Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
11. New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... According to market research "Global ... Demand Forecast to 2022 - Industry Insights by Type ... by P&S Market Research, the global insulin delivery device ... it is expected to grow at a CAGR of ... segment is expected to witness the fastest growth at ...
(Date:5/25/2016)... , May 25, 2016 Digital Health ... to it by the US Patent and Trademark ... technology includes proprietary processes for electronic opt-­in and ... and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for ...
(Date:5/25/2016)... 2016 ReportsnReports.com adds "Chronic ... that provides an overview on therapeutic pipeline of ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Chronic Cough ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... ... for the Foundation Fighting Blindness, Long Island Chapter on June 4, 2016, 1:30-3:30 ... , Dr. Maisel, founder of Retina Group of New York , is ...
(Date:5/26/2016)... ... , ... Memorial Day Weekend marks the unofficial start of summer and the ... make sure your family and vehicle are ready to hit the road this weekend. ... deaths and an additional 50,500 serious injuries from motor vehicle crashes during the three-day ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... The ... to host a six-week smoking cessation class starting June 6 at their clinic in ... http://www.gnahec.org . , Additionally, the Lung Institute has created a free downloadable 4 ...
(Date:5/26/2016)... ... May 26, 2016 , ... American orthopedic ... medical officer of Blue Horizon International (BHI), Brian Mehling, M.D., spoke at an ... during May 5-6, 2016 in Chicago, IL, USA. Dr. Mehling’s presentation was focused ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, a ... first PowerWave Instructor Certification Course in Stoughton, Massachusetts. The course was led by ... through the 8 hour interactive course to qualify participants as certified PowerWave trainers. ...
Breaking Medicine News(10 mins):